Efficacy and Safety of PRP in Patients with Recurrent Implantation
Failure Undergoing ART- A Systematic Review & Meta-analysis
Abstract
Background: RIF is a frustrating condition, both for the clinician and
the patient. Clinical trials have shown that PRP might improve live
birth and clinical pregnancy rate in women with RIF undergoing IVF.
Materials, setting, and methods: An electronic database search of
PubMed, EMBASE, SCOPUS, and Cochrane Central was performed for articles
published in the English language by two independent reviewers using
predefined eligibility criteria Women of reproductive age group
diagnosed with RIF and are planned for IVF cycle with fresh or frozen
embryos were included. Included studies were clinical trials comparing
PRPa against routine care or used as a standalone therapy in patients
with RIF. Bias was assessed using the Cochrane Collaboration Network
Risk of Bias Tool version 2. Quality of evidence was determined and a
summary of findings table was prepared for individual outcomes using
GRADEpro software. Main results and the role of chance: We identified
1146 records, of which, we screened 531 records and ten studies were
included for final review. For live birth rate, we have little
confidence that administration of PRP had any significant effect on live
birth rate (RR 3.01, 95% CI 1.13 to 7.99, I2 = 80%, very low quality
of evidence). Similarly, the quality of evidence was low for clinical
pregnancy rate, we are uncertain that the administration of PRP had any
significant effect on clinical pregnancy rate (RR 2.09, 95% CI 1.71 to
2.55, I2 = 25%). The protocol was registered on PROSPERO (registration
number CRD42021292209).